| Autor: |
Aghaji, AE, Ohaju-Obodo, JO, Osegbe, DN, Mbibu, HN, Maitama, H |
| Jazyk: |
angličtina |
| Rok vydání: |
2004 |
| Předmět: |
|
| Zdroj: |
International Journal of Medicine and Health Development; Vol 9, No 2 (2004); 72-76 |
| ISSN: |
1118-2601 |
| Popis: |
Aim: To assess the therapeutic benefits of Maximum Androgen Blockade and the Tolerability of Bicalutamide, an oral non-steroidal anti-androgen in patients with advanced prostate cancer. Patients and Methods: A total of forty-nine(49) male patients aged between 42 and 84 years with tumour grades T2, T3 and T4 were enrolled in a multi-centre clinical trial to receive bicalutamide 50mg daily following surgical castration. Patients were assessed for disease status, adverse events and quality of life. Results: Thirty-three (33) patients completed the study and had therapy for 48 weeks, 90.9% of whom had complete response while the quality of life due to urinary symptoms was also markedly improved. The profile of adverse events was mild. Conclusion: Bicalutamide given as a daily dose of 50mg in combination with surgical castration is a well tolerated therapy and has therapeutic benefits in African patients with advanced prostate cancer. Key Words: Advanced Prostate Cancer, Surgical Castration, Bicalutamide, Tolerability, Thera-peutic Benefits, Maximum Androgen Blockade. Journal of College of Medicine 2005: 9(2): 72-76 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
